In adult reproduction daily oral contraceptive pills provide women with a means to avoid pregnancy which can support their health and economical situation. For oral contraception to be effective, consistent drug levels must be maintained for prolonged periods, making the efficacy of these drugs dependent on patient adherence.
According to the CDC the effectiveness of these daily contraceptive pills is closer to 91%, with one-third of users reportedly having missed their dose during a menstrual cycle; amongst women using oral contraceptive pills, the chance of pregnancy is about 9% every year.
Now, a study from researchers at Brigham and Women’s Hospital develops a contraceptive pill that only needs to be taken once a month. The team states their slow-release pill can reside in the stomach for days or weeks and has achieved month-long delivery in preclinical models. The opensource study is published in the journal Science Translational Medicine.
Previous studies show several methods for long-term hormonal contraception exist presently including subcutaneous implants, intrauterine devices, vaginal rings, transdermal patches, and injectables. Daily oral pills, however, are favored by a sizeable fraction of the female population, mainly due to their availability, ease of use, the opportunity for self-administration, and rapid renewal of fertility upon discontinuation.
Therefore a long-term oral pill would be highly desirable for the aforementioned reasons. The current study designs and provides preliminary testing of an oral pill in swine proffering month-long delivery of a contraceptive drug, levonorgestrel.
The current study designs a six-armed drug release system joined by an elastomeric core, packaged into a gelatin covered capsule. The six polymeric arms are loaded with the oral contraceptive drug levonorgestrel and folded up into a small, easy-to-swallow capsule.
Once in the stomach, the arms unfold and have a span larger than the opening of the human pylorus, helping the system stay in the stomach where it can release the drug over time. Results show the encapsulation of the contraceptive in polymer matrice successfully protects the drug from the gastric environment and enables sustained release.
The group explains the concentration of the oral contraceptive over time in a pig model was measured in the bloodstream in animals who had been given the coated extended-release form versus an immediate-release tablet. Results show for the tablet, dosage tapered off after six hours, and for the extended-release form, concentrations of the drug were recorded for up to 29 days.
Contraceptive pill stays in the gut
The lab concludes pigs are recognized as having gastric anatomy comparable in dimension to humans, however, transit times are recognized to be slower, therefore a shorter drug release period using a longer residence in the stomach for humans may be needed.
The team surmises they have designed a capsule taken once a month, reside in the stomach and release a drug to prevent pregnancy. For the future, the researchers state work is now underway to bring the extended-release pill closer to human trials by scaling up manufacturing processes and safety evaluations.
Source: Brigham and Women’s Hospital
Don’t miss the latest discoveries from the health innovator community:
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.